Hsbc Holdings PLC Takes Position in Sarepta Therapeutics, Inc. $SRPT

Hsbc Holdings PLC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 70,233 shares of the biotechnology company’s stock, valued at approximately $1,267,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. AQR Capital Management LLC boosted its stake in Sarepta Therapeutics by 214.2% in the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 3,671 shares in the last quarter. Great Lakes Advisors LLC bought a new stake in Sarepta Therapeutics in the first quarter valued at $224,000. Guggenheim Capital LLC raised its stake in Sarepta Therapeutics by 33.5% during the second quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company’s stock worth $783,000 after acquiring an additional 11,497 shares in the last quarter. First Trust Advisors LP raised its stake in Sarepta Therapeutics by 59.2% during the second quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock worth $10,731,000 after acquiring an additional 233,391 shares in the last quarter. Finally, California Public Employees Retirement System lifted its holdings in shares of Sarepta Therapeutics by 7.1% during the second quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company’s stock valued at $1,972,000 after acquiring an additional 7,665 shares during the period. Institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SRPT shares. Wall Street Zen downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a report on Thursday, July 9th. Wolfe Research raised shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, July 9th. Finally, Weiss Ratings lowered shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research report on Wednesday, August 19th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $25.06.

Sarepta Therapeutics Trading Up 0.8%

SRPT stock opened at $21.03 on Tuesday. The business has a fifty day moving average price of $17.79 and a 200 day moving average price of $18.34. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62. Sarepta Therapeutics, Inc. has a fifty-two week low of $14.68 and a fifty-two week high of $25.32. The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of -7.25, a P/E/G ratio of 0.31 and a beta of 0.24.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42. The company had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The business’s revenue was down 34.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.02 earnings per share. Analysts expect that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.